Director Zhang Junge exercises 194,134 Ocugen (OCGN) options, lifts direct stake to 1.36M shares

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Ocugen, Inc. director Zhang Junge exercised stock options to acquire additional common shares. On April 1, 2026, he exercised options covering 194,134 shares of common stock at exercise prices of $0.51, $0.46, and $1.42 per share. Following these exercises, he directly owns 1,359,316 common shares. The options had previously vested and become exercisable between January 2020 and June 2025.

Insider Trade Summary

194,134 shares exercised/converted

Mixed 6 txns

Insider Zhang Junge

Role Director

Type	Security	Shares	Price	Value
Exercise	Option (right to buy)	15,000	$0.00	--
Exercise	Option (right to buy)	112,205	$0.00	--
Exercise	Option (right to buy)	66,929	$0.00	--
Exercise	Common Stock	15,000	$0.51	$8K
Exercise	Common Stock	112,205	$0.46	$52K
Exercise	Common Stock	66,929	$1.42	$95K

Holdings After Transaction: Option (right to buy) — 0 shares (Direct); Common Stock — 1,180,182 shares (Direct)

Footnotes (1)

The option, initially representing a right to purchase 54,000 shares, vested and became exercisable in equal installments over three years commencing on January 2, 2020. The option, representing a right to purchase 112,205 shares, vested and became exercisable on June 9, 2024. The option, representing a right to purchase 66,929 shares, vested and became exercisable on June 28, 2025.

Key Figures

Options exercised: 194,134 shares Exercise price 1: $0.51/share Exercise price 2: $0.46/share +5 more

8 metrics

Options exercised 194,134 shares Total underlying common shares from option exercises on April 1, 2026

Exercise price 1 $0.51/share Option for 15,000 shares of common stock

Exercise price 2 $0.46/share Option for 112,205 shares of common stock

Exercise price 3 $1.42/share Option for 66,929 shares of common stock

Direct holdings after transactions 1,359,316 shares Common stock directly owned after exercises

Option expiration 1 January 2, 2030 Expiration date for option initially for 54,000 shares

Option expiration 2 June 9, 2033 Expiration date for 112,205-share option grant

Option expiration 3 June 28, 2034 Expiration date for 66,929-share option grant

Key Terms

Option (right to buy), Exercise or conversion of derivative security, derivative exercise/conversion, vested and became exercisable, +1 more

5 terms

Option (right to buy) financial

"security_title: "Option (right to buy)""

Exercise or conversion of derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

derivative exercise/conversion financial

"transaction_action: "derivative exercise/conversion""

vested and became exercisable financial

"footnote: "vested and became exercisable on June 9, 2024""

Common Stock financial

"underlying_security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 Insider Transactions: What Each Field Means →

04/02/2026 - 09:26 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zhang Junge

(Last)

(First)

(Middle)

C/O OCUGEN, INC.

11 GREAT VALLEY PARKWAY

(Street)

MALVERN

PENNSYLVANIA

19355

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Ocugen, Inc. [ OCGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/01/2026		M		15,000	A	$0.51	1,180,182	D
Common Stock	04/01/2026		M		112,205	A	$0.46	1,292,387	D
Common Stock	04/01/2026		M		66,929	A	$1.42	1,359,316	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Option (right to buy)	$0.51	04/01/2026		M			15,000	⁽¹⁾	01/02/2030	Common Stock	15,000	$0	0	D
Option (right to buy)	$0.46	04/01/2026		M			112,205	⁽²⁾	06/09/2033	Common Stock	112,205	$0	0	D
Option (right to buy)	$1.42	04/01/2026		M			66,929	⁽³⁾	06/28/2034	Common Stock	66,929	$0	0	D

Explanation of Responses:

1. The option, initially representing a right to purchase 54,000 shares, vested and became exercisable in equal installments over three years commencing on January 2, 2020.

2. The option, representing a right to purchase 112,205 shares, vested and became exercisable on June 9, 2024.

3. The option, representing a right to purchase 66,929 shares, vested and became exercisable on June 28, 2025.

	/s/ Shankar Musunuri, attorney-in-fact	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Ocugen (OCGN) director Zhang Junge report in this Form 4?

Zhang Junge reported exercising stock options to acquire 194,134 Ocugen common shares. These option exercises converted previously granted, vested options into directly held stock, increasing his direct ownership stake to 1,359,316 common shares as of the reported date.

How many Ocugen (OCGN) shares did Zhang Junge acquire through option exercises?

He exercised options for 194,134 Ocugen common shares. The transactions involved three separate option grants that had already vested, converting them into common stock and raising his directly held share count disclosed in the filing.

At what prices were the Ocugen (OCGN) options exercised by Zhang Junge?

The options were exercised at strike prices of $0.51, $0.46, and $1.42 per share. Each price corresponds to a different option grant, all of which had vested before the April 1, 2026 exercise date noted in the Form 4.

What is Zhang Junge’s Ocugen (OCGN) ownership after these transactions?

After the reported option exercises, Zhang Junge directly owns 1,359,316 Ocugen common shares. This figure reflects his position following the conversion of 194,134 option rights into common stock on April 1, 2026, as shown in the filing.

Were any Ocugen (OCGN) shares sold in this Form 4 by Zhang Junge?

No sales were reported. All transactions are coded as option exercises, meaning derivative securities were converted into common stock. The filing shows acquisitions via exercises only, with no dispositions or open-market sales disclosed.

What do the vesting footnotes in the Ocugen (OCGN) Form 4 explain?

The footnotes describe when each option grant vested and became exercisable. One grant vested in three annual installments starting January 2, 2020, while the other grants became fully exercisable on June 9, 2024 and June 28, 2025, respectively.